Search results
Results from the WOW.Com Content Network
These reviews are operated by a group of up to four scientists on a case-by-case scenario. [13] Additionally, research at the labs is overseen by the Institutional Biosafety Committee. The CDC also conducts inspections to assure labs comply with Select Agents rules. [14]
DSAT investigates incidents related to the laboratory use of select agents and toxins and refers cases to the FBI and HHS Office of Inspector General when necessary. [2] They also review experiments that are deemed "restricted experiments" because of their increased risk. [3] Samuel S. Edwin became the director of the division in 2016. [4]
The CDC has regulated the laboratories which may possess, use, or transfer select agents within the United States under the SAP since 2001. The SAP was established to satisfy requirements of the USA PATRIOT Act of 2001 and the Public Health Security and Bioterrorism Preparedness and Response Act of 2002, which were enacted in the wake of the September 11, 2001 attacks and the subsequent 2001 ...
2009: Crown Bioscience US R&D site was founded. 2013: The company acquired PRECOS Ltd. (now Crown Bioscience UK Ltd.), and a bioluminescence imaging platform was established. 2014: Crown Bioscience Taiwan was founded. 2015: The western PDX models were expanded, and the company acquired Molecular Response (now Crown Bioscience San Diego, US).
Since 1997, United States law has declared a list of bio-agents designated by the U.S. Department of Health and Human Services or the U.S. Department of Agriculture that have the "potential to pose a severe threat to public health and safety" to be officially defined as "select agents" and possession or transportation of them are tightly controlled as such. [5]
Emergent BioSolutions was founded on September 5, 1998, by Fuad El-Hibri, under the name BioPort, which had formerly operated as a state-owned entity named Michigan Biological Products Institute [4] and was privatized as Emergent BioSolutions in 2004.
[12] [13] Third-quarter financial reports revealed the price of the Armune Bioscience acquisition to be valued at $12 million, plus $17.5 million in incentives for certain milestones. [14] Later, in October 2018, Exact Sciences announced its purchase of Biomatrica, a developer of sample preservation technology based in San Diego, California.
[1]: 3 [n 1] As of March 2014, the company was based in San Diego, California, and consisted of a single facility. [2]: 58 Ambit made an initial public offering in May 2013, [2] and was listed on the NASDAQ exchange under the symbol "AMBI". [3] Ambit was acquired by Daiichi Sankyo in 2014 and is no longer traded on the NASDAQ exchange. [4]